Dataset Information

Estimating the financial cost of chronic kidney disease to the NHS in England.

ABSTRACT: BACKGROUND:Chronic kidney disease (CKD) is a major challenge for health care systems around the world, and the prevalence rates appear to be increasing. We estimate the costs of CKD in a universal health care system. METHODS:Economic modelling was used to estimate the annual cost of Stages 3-5 CKD to the National Health Service (NHS) in England, including CKD-related prescribing and care, renal replacement therapy (RRT), and excess strokes, myocardial infarctions (MIs) and Methicillin-Resistant Staphylococcus Aureus (MRSA) infections in people with CKD. RESULTS:The cost of CKD to the English NHS in 2009-10 is estimated at £ 1.44 to £ 1.45 billion, which is ? 1.3% of all NHS spending in that year. More than half this sum was spent on RRT, which was provided for 2% of the CKD population. The economic model estimates that ? 7000 excess strokes and 12 000 excess MIs occurred in the CKD population in 2009-10, relative to an age- and gender-matched population without CKD. The cost of excess strokes and MIs is estimated at £ 174-£ 178 million. CONCLUSIONS:The financial impact of CKD is large, with particularly high costs relating to RRT and cardiovascular complications. It is hoped that these detailed cost estimates will be useful in analysing the cost-effectiveness of treatments for CKD.

SUBMITTER: Kerr M

PROVIDER: S-EPMC3484716 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Estimating the financial cost of chronic kidney disease to the NHS in England.

Kerr Marion M Bray Benjamin B Medcalf James J O'Donoghue Donal J DJ Matthews Beverley B

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120805

<h4>Background</h4>Chronic kidney disease (CKD) is a major challenge for health care systems around the world, and the prevalence rates appear to be increasing. We estimate the costs of CKD in a universal health care system.<h4>Methods</h4>Economic modelling was used to estimate the annual cost of Stages 3-5 CKD to the National Health Service (NHS) in England, including CKD-related prescribing and care, renal replacement therapy (RRT), and excess strokes, myocardial infarctions (MIs) and Methici ...[more]

PMID: 22815543

Similar Datasets

Project description:IntroductionChronic kidney disease is frequently encountered in clinical practice and often requires more intricate management strategies. However, its impact on outcomes of patients warranting emergency general surgery has not been well characterized. The present study examined the association of chronic kidney disease stage on in-hospital outcomes and readmission following emergency general surgery using a nationally representative cohort.MethodsThe 2016-2018 Nationwide Readmissions Database was queried to identify all adult hospitalizations for 1 of 6 common emergency general surgery operations. Patients were stratified by severity of chronic kidney disease into stages 1-3, stages 4-5, end-stage renal disease, and others (non-chronic kidney disease). Regression models were used to examine factors associated with mortality, readmissions, and costs.ResultsOf an estimated 985,101 patients undergoing emergency general surgery, 60,949 (6.2%) had a diagnosis of chronic kidney disease (1-3: 67.1%, 4-5: 11.5%, end-stage renal disease: 23.4%). Unadjusted rates of mortality increased with chronic kidney disease in a stepwise manner (2.1% in non-chronic kidney disease to 16.9 in end-stage renal disease, P < .001), as did 90-day readmissions (9.2% to 29.7%, respectively, P < .001). After adjustment, all stages of chronic kidney disease exhibited increases in risk-adjusted rates of mortality (range: 0.2% in chronic kidney disease 1-3 to 12.2% in end-stage renal disease, P < .001). Relative to non-chronic kidney disease, end-stage renal disease had the greatest cost burden for those undergoing small bowel resection (β +$83,600) and the least in cholecystectomy (+$30,400).ConclusionChronic kidney disease severity is associated with a stepwise increase in mortality, hospitalization costs, and 90-day readmissions. Our findings may better inform shared decision-making and have implications in benchmarking. Further studies for optimal management strategies in this high-risk group are needed.

Project description:Background:Health systems are under pressure to deliver more effective care without expansion of resources. This is particularly pertinent to diseases like chronic kidney disease (CKD) that are exacting substantial financial burden to many health systems. The aim of this study is to systematically review the Cost Utility Analysis (CUA) evidence generated across interventions for CKD patients undergoing kidney transplant (KT). Methods:A systemic review of CUA on the interventions for CKD patients undergoing KT was carried out using a search of the MEDLINE, CINAHL, EMBASE, PsycINFO and NHS-EED. The CHEERS checklist was used as a set of good practice criteria in determining the reporting quality of the economic evaluation. Quality of the data used to inform model parameters was determined using the modified hierarchies of data sources. Results:A total of 330 articles identified, 16 met the inclusion criteria. Almost all (n?=?15) the studies were from high income countries. Out of the 24 characteristics assessed in the CHEERS checklist, more than 80% of the selected studies reported 14 of the characteristics. Reporting of the CUA were characterized by lack of transparency of model assumptions, narrow economic perspective and incomplete assessment of the effect of uncertainty in the model parameters on the results. The data used for the economic model were satisfactory quality. The authors of 13 studies reported the intervention as cost saving and improving quality of life, whereas three studies were cost increasing and improving quality of life. In addition to the baseline analysis, sensitivity analysis was performed in all the evaluations except one. Transplanting certain high-risk donor kidneys (high risk of HIV and Hepatitis-C infected kidneys, HLA mismatched kidneys, high Kidney Donor Profile Index) and a payment to living donors, were found to be cost-effective. Conclusions:The quality of economic evaluations reviewed in this paper were assessed to be satisfactory. Implementation of these strategies will significantly impact current systems of KT and require a systematic implementation plan and coordinated efforts from relevant stakeholders.

Dataset Information

Estimating the financial cost of chronic kidney disease to the NHS in England.

Publications

Estimating the financial cost of chronic kidney disease to the NHS in England.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets